Read More Pharma Industry News Mirador Therapeutics licenses long-acting KP-301 antibody from Kira Pharmaceuticals to enter ANCA-associated vasculitis Mirador licenses long-acting anti-C5a antibody KP-301 from Kira, with Phase 1 planned in 2026 and an AAV Phase 2 study targeted for 2027. bySrinathJuly 17, 2026